Oxford coronavirus vaccine found protective in small monkey study
British drugmaker AstraZeneca
last month announced it had teamed up with researchers at the Oxford
Vaccine Group and the Jenner Institute, which are developing the
vaccine.
https://images.jpost.com/image/upload/f_auto,fl_lossy/t_JD_ArticleMainImageFaceDetect/457814Muita uutisia:
https://www.jpost.com/health-science/israeli-disinfectant-kills-100-percent-of-viruses-bacteria-627242
Israeli disinfectant kills 100% of viruses, bacteria
The Israel Institute for
Biological Research developed a disinfectant that kills 100% of viruses
and bacteria, and is currently being used in mikvehs in Bnei Brak.
Israel's IIBR finds antibody that neutralizes coronavirus
IIBR, Yeroham to collaborate on vaccine production facility
Last month, IIBR announced that it had begun testing a COVID-19
vaccine prototype on rodents. The institute was personally asked by
Prime Minister Benjamin Netanyahu to join the fight against the pandemic
in early February.
The
institute is also involved in plasma collection from people who have
recovered from being infected with the new coronavirus, in the hope that
this might help research.
MEANWHILE,
IIBR and the small southern town of Yeroham on Monday night announced
they have big plans to open Israel's first vaccine production facility,
in partnership with one of two prospective international pharmaceutical
companies, according to a spokesperson for the Yeroham local council.
The
Monday night announcement came after a meeting Sunday between the heads
of the IIBR, Yeroham’s local council and the CEO of an international
pharmaceutical company. A model was presented that would allow for the
quick establishment of such a facility, if approved by the Israeli
government.
The
facility can reportedly be built "in the very near future," even before
IIBR completes full development and approvals for its coronavirus
vaccine, which it predicts will be in early 2021.
In
2016, Israel's government adopted decision 120B, which ordered the
establishment of a vaccine plant as a strategic asset for the State of
Israel in the event of a pandemic, after a decade of discussions on the
matter. However, negotiations on the matter had stalled since the
decision was made, and no working models had been agreed upon until
Monday's announcement.
According
to the model, tens of millions of vaccine units of various types will
be manufactured in Yeroham, which will ensure Israeli self-sufficiency
during both regular routine vaccinations and in case of a pandemic.
While
the Yeroham local council plans to provide infrastructure and manpower
and IIBR will provide the research aspect of the deal, the model still
relies on an undecided third partner for international operations,
marketing and distribution purposes.
Negotiations
are currently underway with two of the world's largest international
pharmaceutical companies, one from India and the other from the United
States. At the same time, in the coming days, they will turn to the Bill
and Melinda Gates Fund, which aims to set up vaccination facilities
around the world to help find a vaccine for COVID-19.
IIBR
is not the only Israeli research team that has shared progress on
efforts to develop a vaccine or treatment for the novel virus. MigVax,
an affiliate of the MIGAL Galilee Research Institute, recently reported
that it is close to completing the first phase of development of a
coronavirus vaccine.
Last week, it secured a $12 million investment from OurCrowd to accelerate the path to clinical trials. The company told The Jerusalem Post that is hopes to begin human trials of its oral vaccine as early as June 1.
https://www.jpost.com/health-science/the-great-coronavirus-vaccine-hacking-arms-race-analysis-628055
https://www.jpost.com/health-science/the-great-coronavirus-vaccine-hacking-arms-race-analysis-628055
